PROVIDER PROFILE · NPI 1659531770

Zheng ZhouMD, PH.D

PRACTICEUPSTATE EMERGENCY MEDICINE, INCSee all providers at this practice →

Hematology-OncologySyracuse, NYI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

200

Unique beneficiaries

—

Total services

297

Distinct HCPCS

Medicare payment

$21K

Peer benchmark

Total Medicare services vs. 628 Hematology-Oncology providers in NY — bottom quintile (cohort median 883).

PRESCRIBING · PART D · 2024

Total Rx claims

103

Beneficiaries

—

Total drug cost

$309K

Distinct drugs

Brand share

11.7%

Top prescribed drugs

Hydroxyurea26 claims

Acyclovir16 claims

Ciprofloxacin Hcl13 claims

Prochlorperazine Maleate12 claims

Momelotinib Dihydrochloride12 claims

QUALITY · MIPS · 2024

No data available for this provider in 2024.

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$6K

Payment records

By payment type

Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$4K

Consulting Fee$1K

Food and Beverage$432

REFERRAL NETWORK

Where Zheng Zhou's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 4 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
DESAI, CHARU	22	111
Jan Cerny Hematology-Oncology · Worcester, MA	20	132
YU, HONGBO	16	111
Eric Schmidlin Diagnostic Radiology · Worcester, MA	14	38

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history